|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
645403040[A04200251]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2002.05.11)(ÇöÀç¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»öÀÇ ´çÀÇÁ¤ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
500TABS |
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
´ÙÀ½ Áúȯ¿¡ ÀÖ¾î¼ÀÇ °æ·Ã ¹× ¿îµ¿±â´É Ç×Áø : À§½ÊÀÌÁöÀå±Ë¾ç, ½Äµµ°æ·Ã, À¯¹®¿¬Ãà, À§¿°, Àå¿°, Àå»êÅë, °æ·Ã¼º º¯ºñ, ±â´É¼º¼³»ç, ´ã³¶¿°, ´ã°ü¿°, ´ã¼®Áõ, ´ãµµÀÌ»ó¿îµ¿Áõ, ´ã³¶ÀýÁ¦ÈÄÀÇ ÈÄÀ¯Áõ, ¿ä·Î°á¼®, ¹æ±¤¿°, ¿ù°æ°ï¶õ
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ : ºê·ÒÈºÎÆ¿½ºÄÚÆú¶ó¹ÎÀ¸·Î¼ 1ȸ 10-20§· 1ÀÏ 3-5ȸ °æ±¸Åõ¿©ÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
1) ³ì³»Àå ȯÀÚ
2) À¯¹®ÇùÂø µî À§Àå°üÀÇ ±â´ÉÀû ÇùÂø ȯÀÚ
3) ¸¶ºñ¼º ÀåÆó»ö ȯÀÚ
4) ÁßÁõ ±Ù¹«·ÂÁõ ȯÀÚ
5) °Å´ë °áÀå ȯÀÚ
6) ºÎÁ¤ ºó¸Æ ȯÀÚ
7) ÁßÁõÀÇ ½ÉÁúȯ ȯÀÚ
8) ÀÌ ¾à¿¡ °ú¹ÎÁõ ȯÀÚ
9) ÃâÇ÷¼º ´ëÀå¿° ȯÀÚ
10) Àü¸³¼º ºñ´ë¿¡ ÀÇÇÑ ¹è´¢Àå¾Ö ȯÀÚ
11) µå¹°°Ô ÀÌ ¾àÀÇ Ã·°¡Á¦¿¡ ºÒ³»¼ºÀÇÀ¯ÀüÀû ¼ÒÀÎÀ» °¡Áø ȯÀÚ (ÀÌ ¾àÀº ¹é´çÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î °ú´ç ºÒ³»¼ºÀÇ À¯ÀüÀû ¼ÒÀÎÀ» °¡Áø ȯÀÚ¿¡°Ô´ÂÅõ¿©ÇÏÁö ¸» °Í) (ÇÔÀ¯Á¦Á¦¿¡ ÇÑÇÔ)
|
| ½ÅÁßÅõ¿© |
1) ´ÙÀ½ ȯÀÚ¿¡´Â Åõ¿©ÇÏÁö ¾Ê´Â°ÍÀÌ ¿øÄ¢À̳ª ºÎµæÀÌÇÑ °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. : ¼¼±Õ¼º ¼³»ç ȯÀÚ
2) ¿ïÇ÷¼º ½ÉºÎÀü ȯÀÚ
3) ºÎÁ¤¸Æ ȯÀÚ
4) ±Ë¾ç¼º ´ëÀå¿° ȯÀÚ(Áßµ¶¼º°Å´ë°áÀåÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.)
5) °©»ó¼± ±â´É Ç×ÁøÁõ ȯÀÚ
6) °í¿Â ȯ°æ¿¡ Àִ ȯÀÚ
7) Àü¸³¼± ºñ´ë ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
º¸°íµÈ ÀÌ»ó¹ÝÀÀµé Áß ¸¹Àº °ÍµéÀÌÀÌ ¾àÀÇ Ç×Äݸ°¼º Ư¼º¿¡ ±âÀÎÇÑ °ÍÀ̾ú´Ù. ÀÌ ¾àÀÇ Ç×Äݸ°¼º ÀÌ»ó¹ÝÀÀÀº ÀϹÝÀûÀ¸·Î °æ¹ÌÇϰí Á¦ÇÑÀûÀ̾ú´Ù.
1) ¸é¿ª±â°è : ¾Æ³ªÇʶô½Ã½º ¼ï, ¾Æ³ªÇʶô½Ã½º ¹ÝÀÀ(±¸¿ª, ±¸Åä, ¿ÀÇÑ, ÇǺÎâ¹é, Ç÷¾ÐÀúÇÏ, È£Èí°ï¶õ, ±â°üÁö ¿¬Ãà, ºÎÁ¾, Ç÷°üºÎÁ¾ µî)À̳ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ ½Ç½ÃÇÏ¿© ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â ÀÌ ¾àÀÇ Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ½Ç½ÃÇÑ´Ù. ¶ÇÇÑ ÇǺιÝÀÀ ¹× ´Ù¸¥ °ú¹ÎÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) ´« : ¶§¶§·Î »êµ¿, ¸ð¾ç±Ù¸¶ºñ, Á¶ÀýÀå¾Ö µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ¼Òȱâ°è : ±¸°°ÇÁ¶, ±¸°¥, ±¸¿ª, ±¸Åä, º¯ºñ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) ½ÅÀå ¹× ºñ´¢±â°è : ¶§¶§·Î ¹è´¢Àå¾Ö, ´¢Àú·ù°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) Á¤½Å½Å°æ°è : ¶§¶§·Î µÎÅë, µÎÁß°¨ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç °ú·®Åõ¿©½Ã ºÒ¾È, ÈïºÐ, ȯ°¢ ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
6) ½ÉÇ÷°ü°è : ½É°èÇ×Áø, ºó¸Æ, Ç÷¾ÐÀúÇÏ, ¾îÁö·¯¿ò, ¾È¸éÈ«Á¶°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
7) ÇǺΠ¹× ºÎ¼Ó±â°ü : ¹ßÇÑÀå¾Ö
8) ±âŸ : ¶§¶§·Î ÀÌ»ó°í¿ µîÀ̳ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) Æä³ëÄ¡¾ÆÁø°è ¾à¹°, »ïȯ°è Ç׿ì¿ï¾à, MAO ÀúÇØÁ¦,Ç×È÷½ºÅ¸¹ÎÁ¦, Äû´Ïµò, ¾Æ¸¸Å¸µò, µð¼ÒÇǶó¹Ìµå¿Í °°Àº Ç×Äݸ°¼º ¾à¹° ¹× ´Ù¸¥ Ç×Äݸ°Á¦(Ƽ¿ÀÆ®·ÎÇÇ¿ò, ÀÌÆ®¶óÆ®·ÎÇÇ¿ò)¿Í º´¿ë½Ã Ç×Äݸ° ÀÛ¿ëÀÌ Áõ°µÉ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù.
2) ¸ÞÅäŬ·ÎÇÁ¶ó¹Ìµå µîÀÇ µµÆÄ¹Î±æÇ×¾à°ú º´¿ëÅõ¿©½Ã À§Àå°ü¿¡ ´ëÇÑ µÎ ¾à¹°ÀÇ È¿°ú°¡ ¸ðµÎ °¨¾àµÉ ¼ö ÀÖ´Ù.
3) º£Å¸ 1È¿´É¾à°ú º´¿ë½Ã º£Å¸ È¿´É¾àÀÇ ½É¹ÚÁõ°¡ÀÛ¿ëÀÌ Áõ°µÉ ¼ö ÀÖ´Ù.
|
| Off-label Usage |
[Á¶È¸]
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Scopolamine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Scopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center).
|
| Pharmacology |
Scopolamine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Scopolamine is a muscarinic antagonist structurally similar to the neurotransmitter acetylcholine and acts by blocking the muscarinic acetylcholine receptors and is thus classified as an anticholinergic. Scopolamine has many uses including the prevention of motion sickness. It is not clear how Scopolamine prevents nausea and vomiting due to motion sickness. The vestibular part of the ear is very important for balance. When a person becomes disoriented due to motion, the vestibule sends a signal through nerves to the vomiting center in the brain, and vomiting occurs. Acetylcholine is a chemical that nerves use to transmit messages to each other. It is believe that Scopolamine prevents communication between the nerves of the vestibule and the vomiting center in the brain by blocking the action of acetylcholine. Scopolamine also may work directly on the vomiting center. Scopolamine must be taken before the onset of motion sickness to be effective.
|
| Metabolism |
Scopolamine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Not Available
|
| Protein Binding |
Scopolamine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Scopolamine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Scopolamine¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
Scopolamine butylbromideÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : ½ÊÀÌÁöÀå ¸¶ºñ : 20-120 ÃÊ (IV), 3-5 ºÐ(IM)
- ÀÛ¿ëÁö¼Ó½Ã°£ : ½ÊÀÌÁöÀå ¸¶ºñ : 3.7-20 ºÐ (IV), 14.6ºÐ (IM)
- ÃÖ°íÇ÷Áß³óµµ µµ´Þ½Ã°£ : °æ±¸ : 1-2 ½Ã°£
- »ýü³»ÀÌ¿ë·ü : °æ±¸ : 8-10%
- ºÐÆ÷ :
- À§Àå°ü, ½ÅÀå, °£¿¡ ³ôÀº ³óµµ·Î ºÐÆ÷ÇÑ´Ù.
- ºÐÆ÷ ¹Ý°¨±â : 3.9 ºÐ
- ºÐÆ÷¿ëÀû : 3.5 L/kg
- ´Ü¹é°áÇÕ : 3-11%
- ´ë»ç : ÀϺκÐÀÌ °£¿¡¼ ºñȰ¼º ´ë»çü·Î ´ë»çµÈ´Ù.
- ¼Ò½Ç ¹Ý°¨±â : 5.1 ½Ã°£ , Á¤¸Æ ÁÖ»ç½Ã 3°³ÀÇ ¼Ò½Ç»óÀ» °¡Áö¸ç alpha »óÀÇ ¹Ý°¨±â = 3.9 ºÐ, beta »óÀÇ ¹Ý°¨±â = 30 ºÐ, ¸¶Áö¸· »óÀÇ ¹Ý°¨±â = 5.1 ½Ã°£ÀÌ´Ù.
- ¼Ò½Ç : Á¤¸ÆÅõ¿© : 42-50%°¡ ¹Ìº¯Èü·Î ½Å¹è¼³µÇ¸ç ´ëº¯À¸·Î 37%°¡ ¹è¼³µÊ
- °æ±¸ : 0.7-2%°¡ ¼Òº¯À¸·Î ¹è¼³µÇ¸ç ´ëº¯À¸·Î 90%±îÁö ¹è¼³µÊ.
- ´ãÁó¹è¼³ : 0.5%
|
| Biotransformation |
Scopolamine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Scopolamine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Scopolamine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Scopolamine¿¡ ´ëÇÑ Description Á¤º¸ An alkaloid from Solanaceae, especially Datura metel L. and Scopola carniolica. Scopolamine and its quaternary derivatives act as antimuscarinics like atropine, but may have more central nervous system effects. Among the many uses are as an anesthetic premedication, in urinary incontinence, in motion sickness, as an antispasmodic, and as a mydriatic and cycloplegic. [PubChem]
|
| Dosage Form |
Scopolamine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Disc TransdermalLiquid IntravenousSolution IntramuscularSolution IntravenousTablet Oral
|
| Drug Category |
Scopolamine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AdjuvantsAdjuvants, AnesthesiaAntimuscarinicsAntispasmodicsCholinergic AntagonistsMuscarinic AntagonistsMydriatics
|
| Smiles String Canonical |
Scopolamine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN1C2CC(CC1C1OC21)OC(=O)C(CO)C1=CC=CC=C1
|
| Smiles String Isomeric |
Scopolamine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@@H](CO)C1=CC=CC=C1
|
| InChI Identifier |
Scopolamine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3
|
| Chemical IUPAC Name |
Scopolamine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ Not Available
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-07-25
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|